Photocure
Manufacturing · Norway · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hoffsveien 4, Oslo, Oslo, 0275, NorwayPhone Number
+47 22062210Website
www.photocure.comRevenue
$55.2 MillionStock Symbol
PHOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Photocure
Photocure, the world leader in photodynamic technology, is a Norwegian based specialty pharmaceutical company. Photocure develop and commercialize highly selective and effective solutions in several disease areas such as bladder cancer, HPV and precancerous lesions of the cervix and acne. Their aim is to improve patient care and quality of life by making solutions based on Photocure Technology accessible to patients worldwide. Photocure was founded by the Norwegian Radium Hospital in 1997. Today the company is headquartered in Oslo, Norway.Explore more
Photocure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Photocure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Photocure launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Photocure had a recent Job posting/layoffs
Earning: See what the market has to say on Photocure recently announced quarterly report
Funding: Get notified immidiatlly once Photocure has new funding data
Congratulate Masked Content for being promoted to Masked Content at Photocure
Photocure, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Photocure has recently received funding, and reach out quickly before it becomes old news!
Check out if Photocure is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Photocure as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Photocure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Photocure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Photocure.
Photocure Tech Stack
A closer look at the technologies used by Photocure
Most Recent Scoops
Project
Photocure has announced that the FDA reaffirmed plans to begin the proposed reclassification process for blue light cystoscopy equipment in the second half of this year, which is expected to significantly expand the US addressable market and accelerate adoption over time.
Healthcare Technology
Earnings
Photocure has reported a financial gain of NOK 7.7 million in Q2 2026, primarily driven by foreign exchange gains on intercompany loans and on the deferred Vesica Health transaction liability, partially offset by Ipsen earn-out payments, resulting in a net loss of NOK 0.7 million for the quarter after NOK 1 million in tax expenses.
Earnings
Photocure has reported operating expenses of NOK 134.1 million for Q2 2026, an increase of 21% versus the prior year, including NOK 21.8 million in business development expenses related to the Vesica Health transaction, with normalized operating expense growth of approximately 5% when excluding those items and the impact of previously open positions now filled.
Earnings, Finance
Earnings
Photocure has reported total revenue of NOK 142.5 million for Q2 2026, compared to NOK 135.6 million in Q2 2025, including NOK 140 million in Hexvix product revenue representing an 11% increase at constant currency, with gross profit of NOK 132.1 million and a Hexvix gross margin of 93%.
Earnings, Finance
Earnings
Earnings, Finance
Photocure News & Media
Photocure ASA: Results for the second quarter of 2026
OSLO, Norway, July 29, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 140.0 million in the second quarter of 2026 (Q2 2025: NOK 135.6 million), and an adjusted EBITDA of NOK 27.2 million (Q2 2025: NOK 27.0 million) for the company. In 2026,...Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses Photocure's blue light cystoscopy (BLC®) registry in bladder...Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses Photocure's blue light cystoscopy (BLC®) registry in bladder...Photocure ASA (PHCUF) M&A Call Transcript
Photocure ASA (PHCUF) M&A Call June 5, 2026 5:00 AM EDTCompany ParticipantsDaniel Schneider - President & CEOChristopher Thibodeau - CEO, CFO,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Photocure
Sign Up For FreeTo access detailed company insights
Photocure, the world leader in photodynamic technology, is a Norwegian based specialty pharmaceutical company. Photocure develop and commercialize highly selective and effective solutions in several disease areas such as bladder cancer, HPV and precancerous lesions of the cervix and acne. Their aim is to improve patient care and quality of life by... Read More
